Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02405260 | Add Glucokinase Activator to Target A1c | PHASE2 | COMPLETED | 190 | — | — | Mar 1, 2015 | Sep 1, 2016 | Feb 10, 2017 | 20 | United States |
| Arm | Type | Description |
|---|---|---|
| TTP399 400 mg | EXPERIMENTAL | TTP399 once daily |
| TTP399 800 mg | EXPERIMENTAL | TTP399 once daily |
| Sitagliptin 100 mg | ACTIVE_COMPARATOR | Sitagliptin once daily |
| Placebo | PLACEBO_COMPARATOR | Placebo once daily |
| Name | Type | Description |
|---|---|---|
| TTP399 400 mg | DRUG | once daily |
| TTP399 800 mg | DRUG | once daily |
| Sitagliptin 100 mg | DRUG | once daily |
| Placebo | DRUG | once daily |
Inclusion Criteria: * A historical diagnosis of Type 2 Diabetes in accordance with the American Diabetes Association (ADA) guidelines, with diagnosis at least 6 months prior to Screening. * On a stable (for the last 3 months prior to screening) regimen of metformin monotherapy equivalent of at leas...